美国安进地诺单抗去哪买的到？

The original drug was developed by Amgen in the United States and is currently approved for multiple indications around the world. Denosumab's mechanism of action: Denosumab binds to RANKL, a transmembrane or soluble protein that plays an important role in the formation, function, survival of osteoclasts and cells responsible for bone resorption, regulating the release of calcium from bone. Through RANKL stimulation, osteoclast activity is enhanced, mediating the occurrence of bone metastasis bone pathology in solid tumors. In addition, giant cell tumors of bone contain stromal cells that express RANKL, and osteoclast-like giant cells express RANKL receptors, which signal to each other leading to osteolysis and tumor growth. Denosumab prevents RANKL from activating its receptor RANK expressed on the surface of osteoclasts, precursor cells, and osteoclast-like giant cells.

In a phase II clinical trial, 282 patients were divided into 3 groups, group 1 was patients with unresectable GCTB, group 2 was patients with postoperative GCTB with severe surgical complications, and group 3 was patients previously studied with denosumab. In group 1, 96% of patients showed no progression after 13 months of follow-up, in group 2, 74% of patients did not undergo surgery after 9.2 months of follow-up, and 62% of patients underwent surgery with fewer complications. The pain was significantly reduced after 2 months of use. PET-CT is also supported.

Where can I buy Amgen denosumab in the United States? American Amgen has been launched in the United States, China, Türkiye and other places, and patients can purchase it in the regions where it is listed. Among them, the Turkish version is much cheaper than the United States and China. Medical Travel is an overseas medical service company. If you want to buy authentic denosumab, you can contact us. Medical Travel cooperates with foreign pharmacies and hospitals to help patients purchase authentic and guaranteed denosumab without going abroad.

Recommended hot articles: /newsDetail/85794.html